Skip to main content

Market Overview

UPDATE: Barclays Capital Initiates Coverage On Celgene On Long-Term Upside Potential


In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Celgene Corporation (NASDAQ: CELG) with an Equal-Weight rating and $120.00 price target.

In the report, Barclays Capital noted, “The key drivers for Celgene's core Revlimid/Pomalyst/Abraxane franchises are approval for Revlimid in newly diagnosed myeloma in the US/EU and the EU rollout of Abraxane for pancreatic cancer. We believe that this is reflected in the consensus of ~20% revenue growth; when looking at upside potential, it is weighted to 2016, not 2015. Longer term, the Street has been focused on the 2017 outlook and while we're impressed with Celgene's partnered pipeline (Agios, Acceleron, Epizyme, etc.) and phase 2 data for GED-0301 (mongersen) in Crohn's disease, neither should materially alter this outlook. Overall, while fundamentals are solid for Celgene, the upside levers are known and may not begin to play out until 2016 and there are fewer pipeline de-risking events in 2015. Hence, we're initiating coverage with an Equal Weight rating and $120 price target.”

Celgene closed on Monday at $11.93.

Latest Ratings for CELG

Nov 2019Standpoint ResearchDowngradesBuyHold
Nov 2019BairdDowngradesOutperformNeutral
May 2019BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings


Related Articles (CELG)

View Comments and Join the Discussion!

Posted-In: Barclays Capital Geoffrey MeachamAnalyst Color Initiation Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at